E. Coli 0157-H7 Countagious Toxic Bacteria Infectious Disease Epidemc Cure Research & Development.

WORLD E. COLI 0157-H7 CONTAGIOUS TOXIC BACTERIA INFECTIOUS DISEASE EPIDEMY, HEALTH PROTECTION MANAGEMENT AND CURE RESEARCH & DEVELOPMENT ANSWER, ALL BY THE WORLD’S JOIN EFFORT SET COOPERATION AND COORDINATION SENSE ORG. WORK.

SPECIALLY ELIMINATE THE NEW WORLD ORDER EPIDEMIES CAUSE BY THE BACTERIAS AIRCRAFTS SPRAY OVER AS ATMOSPHERE CHEMTRAIL

Since the actual E. Coli 0157-H7 contagious toxic bacteria infectious disease world epidemy emergency, are necessary the Bacteria spread on food void by Right Antibody farms animals fee and plantations fumigations. Coordinate the Contagious end by Governments Police Migrations Departments join at Health & Military personal Quarantines management. Being Antibody Research & Development lethal ill cure answer come from the World’s Governments subsidies to Health Branches and Labs, share the research answers to investigators ideas feed, to the new medicine Internet Network cure speed finds and world security links. Like the World’s Epidemics Cure join work organization, for the planet population good health sense unite protection.

WORLD EPIDEMIES MAP:

https://www.healthmap.org/                                                          

ESCHERICHIA COLI.

https://en.wikipedia.org/wiki/Escherichia_coli

HEMOLYTIC UREMIC SYNDROME.

https://en.wikipedia.org/wiki/Hemolytic-uremic_syndrome

SHIGA TOXIN E. COLI PRODUCER.

https://en.wikipedia.org/wiki/Shiga-like_toxin-producing_Escherichia_coli

E. COLI 0157-H7 ACADEMIC RESEARCH.

https://www.thelancet.com/search/results?searchTerm=e+coli+0157-h7&fieldName=AllFields&journalFromWhichSearchStarted= 

U.S. CDC E. COLI EPIDEMY CONTROL.

https://www.cdc.gov/ecoli/

E. COLI PATIENTS ORG.

https://ericsecho.org/

E. COLI PUBLIC GENERAL INFORMATION.

https://familydoctor.org/online/famdocen/home/common/digestive/disorders/242.html

ACTUAL E. COLI ANTIBODY CURE RESEARCH ANSWER:

https://www.sciencedaily.com/releases/2011/05/110531115402.htm

Antibodies Successful in Treatment of the Hemolytic-Uremic Syndrome from Enterohemorrhagic Escherichia Coli

ScienceDaily (June 1, 2011) — In the online version of the New England Journal of Medicine, physicians and scientists in Heidelberg, Montreal, and Paris reported on the successful treatment of three young children who were suffering from a severe hemolytic-uremic syndrome (HUS) after an infection with enterohemorrhagic Escherichia coli (EHEC). The infections occurred in 2010. EHEC are the bacteria that cause the current wave of infections that have already claimed ten lives in Germany. The number of suspected and confirmed cases of EHEC has now reached 700.

Eculizumab has been approved in Germany since 2007 and is used to treat a rare blood disease and a rare congenital form of HUS. Two years ago, American physicians reported similar success in children with this form of HUS (NEJM 2009; 360:544-546).

The children suffered from kidney failure and severe neurological disorders. "After several exchanges of blood plasma had no effect, we decided to attempt treatment with Eculizumab," reports Professor Dr. Franz Schaefer, head of the section of Pediatric Nephrology at the Center for Child and Adolescent Medicine at Heidelberg University Hospital.

Within 24 hours of the initial infusion, which was repeated once or twice at intervals of seven days, the clinical condition of the children improved dramatically. Dialysis due to acute kidney failure from HUS could be discontinued. All three children recovered and had no sequelae even six months after the illness.

The researchers decided on using the monoclonal antibody Eculizumab as it interrupts the destructive immune reactions that occur after an infection with EHEC. Eculizumab binds to protein C5, which activates what is called the complement cascade and lead to the destruction of blood cells among other things. With EHEC infections there can also be complement activation, triggered by the Shiga toxin formed by the bacteria.

"We now hope that these results will help the acutely ill patients," said Professor Schaefer. He assumes that even adult patients can profit from therapy with the antibody. "Because of the epidemic in Germany, the publishers of the New England Journal of Medicine decided to accelerate the publishing date of the article, which they have had since February, and they published it immediately after reviewing it," said Schaefer. In addition, the article was sent to all kidney specialists in Germany.

Meanwhile, first treatments of adults and children in German hospitals have started. The German Society of Nephrologists has issued guidelines that the antibody may be given if all others standard treatments like dialysis and plasmapheresis have failed.